Systematic review shows higher THC products provide short-term pain relief for adults — Evidence Review
Published in Annals of Internal Medicine, by researchers from Oregon Health & Science University
Researched by
— the AI search engine for science
Table of Contents
Cannabis products high in THC may offer small, short-term pain relief for chronic pain, but with increased side effects; products low in THC, including CBD-only formulations, do not appear to meaningfully reduce pain. Related studies generally support these findings, noting modest benefits for some patients and highlighting concerns about adverse events and unclear long-term safety—see the recent publication in the Annals of Internal Medicine.
- Several systematic reviews and meta-analyses have found that cannabis-based medicines, particularly those with both THC and CBD, may result in modest pain relief—primarily in neuropathic pain—though the clinical significance of these effects remains uncertain and is often offset by increased rates of adverse events 1 4.
- Evidence from observational and open-label studies suggests potential improvements in pain and function, and possible reductions in opioid use, but these studies are limited by non-randomized designs and increased risk of non-serious side effects 3 5.
- Across the literature, a consistent theme emerges: while cannabis-based medicines may help some individuals with chronic pain, the benefits are generally small, adverse events are common, and more research is needed to establish long-term safety and efficacy 1 2 3 4 5.
Study Overview and Key Findings
The growing use of cannabis-based products for chronic pain management has prompted renewed scrutiny of their efficacy and safety. As more jurisdictions legalize medicinal and recreational cannabis, patients and clinicians are seeking clear, evidence-based guidance. This new systematic review, published in December 2025, addresses these concerns by rigorously evaluating the short-term benefits and harms of cannabis products with varying ratios of THC and CBD in adults with chronic pain. The review also highlights the need for more research on commonly used cannabis formulations that have not yet been extensively studied in clinical trials.
| Property | Value |
|---|---|
| Organization | Oregon Health & Science University |
| Journal Name | Annals of Internal Medicine |
| Population | Adults with chronic pain |
| Sample Size | more than 2,300 adults |
| Methods | Systematic Review |
| Outcome | Pain severity, physical function, adverse events |
| Results | Higher THC products showed small, short-term pain improvements. |
Literature Review: Related Studies
To understand how these new findings fit within the broader research landscape, we searched the Consensus database of over 200 million research papers. The following search queries were used to identify relevant studies:
- cannabis chronic pain treatment efficacy
- THC products short-term pain relief
- cannabis pain management clinical studies
Below, we summarize the key thematic questions and findings from the related literature:
| Topic | Key Findings |
|---|---|
| What is the effectiveness of cannabis-based medicines for chronic pain? | - Cannabis-based medicines may provide modest pain relief in chronic and neuropathic pain, with effects often described as small or limited 1 2 4. - Some studies report improvements in pain and function, as well as reductions in opioid use, though evidence is stronger in non-randomized settings 5. |
| What are the risks and adverse events associated with cannabis use for pain? | - Higher rates of non-serious adverse events (e.g., dizziness, sedation, nausea) are common with cannabis-based treatments, particularly those high in THC 1 3 4. - Serious adverse events are not consistently increased, but long-term safety remains inadequately studied 1 3. |
| Does cannabis-based treatment reduce opioid use or other medication reliance? | - Some observational studies suggest that medicinal cannabis can reduce opioid consumption among chronic pain patients 2 5. - Evidence for this effect is preliminary, and more controlled trials are needed to confirm these findings 2 5. |
| What are the long-term safety and efficacy outcomes of cannabis for chronic pain? | - Most studies are short-term, with durations rarely exceeding 6 months, leaving long-term benefits and risks largely unknown 1 3 4. - Existing evidence calls for more high-quality, long-term research to guide clinical and policy decisions 1 2 4. |
What is the effectiveness of cannabis-based medicines for chronic pain?
The new systematic review aligns with prior evidence indicating that cannabis-based medicines, especially those containing THC, may offer small, short-term improvements in pain—mainly for neuropathic pain—but the clinical relevance is limited. Related systematic reviews and meta-analyses have reached similar conclusions, highlighting modest pain reductions but inconsistent results across studies and patient populations 1 2 4.
- Multiple reviews report that the proportion of patients achieving meaningful pain relief is small, with number-needed-to-treat values indicating modest efficacy 1 4.
- Some open-label and non-randomized studies show greater improvements, but these results are at risk of bias and may overestimate effectiveness 5.
- The effectiveness appears stronger for neuropathic pain than for other chronic pain conditions 1 4.
- Placebo comparisons often reveal that absolute differences in pain scores are minor, and not all formulations or administration routes are equally effective 1 4.
What are the risks and adverse events associated with cannabis use for pain?
Consistent with the new review, existing studies emphasize that adverse events—particularly non-serious ones such as dizziness, sedation, and gastrointestinal symptoms—are common with cannabis-based treatments, especially those high in THC. The risk of serious adverse events is less clear, and most studies are not powered to detect rare outcomes 1 3 4.
- Systematic reviews have found that patients using cannabis-based medicines are more likely to withdraw from studies due to adverse events compared to placebo 1.
- Observational research shows a higher risk of non-serious adverse events among cannabis users, though not for serious adverse events at typical doses 3.
- Central nervous system and psychiatric side effects are among the most frequently reported 1 4.
- The frequency and severity of adverse events may depend on the route of administration and the THC/CBD content 4.
Does cannabis-based treatment reduce opioid use or other medication reliance?
Some studies, particularly observational and open-label designs, report that medicinal cannabis use is associated with reduced opioid consumption in chronic pain patients. However, these findings are not yet robustly supported by randomized controlled trials 2 5.
- Open-label data indicate significant reductions in opioid use following initiation of medicinal cannabis 5.
- Reviews note a possible trend toward reduced reliance on opioids, though causality remains unproven 2.
- The potential for cannabis to serve as an opioid-sparing therapy is of high clinical interest but requires further study 2 5.
- Most controlled trials have not been designed to assess opioid-sparing effects as a primary outcome 2.
What are the long-term safety and efficacy outcomes of cannabis for chronic pain?
A major limitation across the literature is the short duration of most trials, making it difficult to assess long-term safety and efficacy. The new review reinforces this gap, calling for more prolonged, high-quality studies 1 3 4.
- Most randomized studies last only a few weeks to months, which is insufficient to capture long-term effects 1 4.
- Observational research with up to 1-year follow-up suggests a reasonable safety profile for experienced users, but broader generalizability is uncertain 3.
- There is little information on the potential for tolerance, dependence, or other long-term complications 1 3.
- Experts consistently recommend additional research to inform the long-term management of chronic pain with cannabis-based products 1 2 4.
Future Research Questions
Despite growing evidence, many questions remain about the safe and effective use of cannabis-based products for chronic pain. Gaps include the long-term impact of these treatments, optimal dosing strategies, comparative effectiveness with other therapies, and the mechanisms underlying potential opioid-sparing effects. Addressing these questions will help guide clinical practice and policy decisions.
| Research Question | Relevance |
|---|---|
| What are the long-term safety and efficacy outcomes of cannabis-based products for chronic pain? | Most studies are short-term; understanding long-term benefits and risks is essential for chronic pain management 1 3 4. |
| How do different THC to CBD ratios impact the balance between benefit and adverse events in chronic pain? | The new review shows variable effects based on THC/CBD content, but many common formulations remain unstudied 1 4. |
| Can medicinal cannabis reduce opioid use among patients with chronic pain? | Observational studies suggest reductions in opioid use, but randomized data are lacking to confirm this potentially important benefit 2 5. |
| What are the comparative effectiveness and safety of cannabis-based products versus other chronic pain treatments? | Comparative trials with standard treatments (e.g., opioids, anticonvulsants) are rare; such data would inform clinical decision-making 1 4. |
| What are the mechanisms underlying the potential opioid-sparing effects of cannabis in chronic pain patients? | Understanding mechanisms could guide safer integration of cannabis with other analgesics and improve pain management strategies 2 5. |